Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

Despite Pressure from Trump, Pfizer CEO Says Company to Return to Drug Price Increases “As Normal”

By Catherine Sbeglia | October 31, 2018

Pfizer CEO Ian Read said on Tuesday that the company will likely return to “business as normal” at the start of next year in regard to drug prices, despite ongoing pressure from the Trump administration.

After Trump singled out Pfizer on Twitter, the company delayed a planned price hike for nearly 100 drugs. Read and Trump met and agreed that Pfizer would defer the hikes until the end of the year, or when Trump’s proposed blueprint targeting soaring drug prices came into effect, a decision that garnered praise from the president.

However, Read now says it is unlikely that the blueprint will come to fruition by the start of 2019. “I don’t think our pricing situation has changed,” Read remarked, adding “I have, at this moment in time, no different view about how we will take price increases as we did last year […] I feel that they’ve been less rapid than I’d have liked on this discount issue.” 

Read has also expressed criticism of the Trump administration’s recent proposal to link Medicare Part B prices to an international average. The regulation would establish an international pricing index (IPI) that would be used as a reference to set prices paid for drugs through Medicare Part B. The Department of Health and Human Services (HHS) estimated that the IPI model would provide $17.2 billion in savings to patients and taxpayers over a five-year period.

Read, however, commented, “we would hope that the administration would reconsider its position on that.”

It appears the administration is no longer relying on voluntary actions from drug manufacturers, as is evident with this latest proposal, as well as the proposal that came earlier this month that would require pharmaceutical companies to provide the list prices of certain drugs in direct-to-consumer advertisements. The proposal, drafted as a new federal rule, would require drug manufacturers to disclose in ads the list price of a 30-day supply of any drug that is covered through Medicare and Medicaid and costs more than $35 a month.

(Source: The Hill)

 

Related Articles Read More >

Doctor, woman patient and tablet for consulting with results, medical info and talk for healthcare with mockup space. Japanese medic, digital touchscreen or show video for surgery, wellness or advice.
Putting patients first in clinical trials
Confidently navigate the transition from bench to batch
Merck
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE